白细胞介素17A在银屑病发病及治疗中的研究进展

doi:10.35541/cjd.20190430

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (5): 390-394.doi: 10.35541/cjd.20190430

白细胞介素17A在银屑病发病及治疗中的研究进展

朱冠男王刚

第四军医大学西京皮肤医院，西安 710032

收稿日期:2019-03-26 修回日期:2019-09-21 发布日期:2020-04-30
通讯作者: 王刚 E-mail:xjwgang@fmmu.edu.cn
基金资助:
陕西省重点研发计划课题（2018SF-334）

Role of interleukin-17A in the occurrence and treatment of psoriasis

Zhu Guannan, Wang Gang

Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi′an 710032, China

Received:2019-03-26 Revised:2019-09-21 Published:2020-04-30
Contact: Wang Gang E-mail:xjwgang@fmmu.edu.cn
Supported by:
Key Research and Development Program of Shaanxi Province of China （2018SF-334）

摘要/Abstract

摘要： 【摘要】近十余年来的基础和临床研究发现并确立了Th17/白细胞介素17A（IL-17A）在银屑病发病中的核心地位。IL-17A不仅能影响角质形成细胞的增殖活性和细胞功能，对银屑病免疫病理环境中的免疫细胞和相关细胞因子也有很重要的调控作用。近年来针对IL-17A通路的单抗如司库奇尤单抗、ixekizumab、brodalumab等在国内外陆续上市，在临床应用中展现出了显著的疗效。本文介绍IL-17A在银屑病发病机制中的作用以及靶向IL-17A及其受体IL-17RA生物治疗的最新进展。

关键词: 银屑病； Th17细胞；抗体, 单克隆；白细胞介素17A

Abstract: 【Abstract】 In the last 10 years, emerging evidence from basic researches and clinical trials have revealed and confirmed a critical role of Th17/interleukin-17A （IL-17A） in the occurrence of psoriasis. Besides affecting the proliferative activity and functions of keratinocytes, IL-17A also plays an important role in the regulation of immune cells and related cytokines in the immune microenvironment in psoriasis. In recent years, monoclo20190138nal antibodies targeting the IL-17A pathway, such as Secukinumab, Ixekizumab and Brodalumab, have been successively marketed in China and other countries, and have exhibited marked efficacy in clinical practice. This review summarizes latest advances in the role of IL-17A in the pathogenesis of psoriasis as well as in biotherapies targeting IL-17A and its receptor IL-17RA.

Key words: Psoriasis, Th17 cells, Antibodies, monoclonal, Interleukin-17A

朱冠男王刚. 白细胞介素17A在银屑病发病及治疗中的研究进展[J]. 中华皮肤科杂志, 2020,53(5):390-394. doi:10.35541/cjd.20190430

Zhu Guannan, Wang Gang. Role of interleukin-17A in the occurrence and treatment of psoriasis[J]. Chinese Journal of Dermatology, 2020, 53(5): 390-394.doi:10.35541/cjd.20190430

参考文献 36

［1］	Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis［J］. J Am Acad Dermatol, 2014,71（1）:141⁃150. doi: 10.1016/j.jaad.2013.12.036.
［2］	马蕾, 薛海波, 高梅兰, 等. Notch1信号对银屑病患者外周血Th17细胞分化和功能的影响［J］. 中华皮肤科杂志, 2018,51（3）:189⁃193. doi: 10.3760/cma.j.issn.0412⁃4030.2018.03.006.
［3］	Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis［J］. Clin Exp Dermatol, 2010,35（6）:645⁃649. doi: 10.1111/j.1365⁃2230. 2009.03704.x.
［4］	Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis［J］. J Invest Dermatol, 2010,130（5）:1373⁃1383. doi: 10.1038/jid.2009.399.
［5］	Zhang L, Yang XQ, Cheng J, et al. Increased Th17 cells are accompanied by FoxP3（+） Treg cell accumulation and correlated with psoriasis disease severity［J］. Clin Immunol, 2010,135（1）:108⁃117. doi: 10.1016/j.clim.2009.11.008.
［6］	Brembilla NC, Senra L, Boehncke WH. The IL⁃17 family of cytokines in psoriasis: IL⁃17A and beyond［J］. Front Immunol, 2018,9:1682. doi: 10.3389/fimmu.2018.01682.
［7］	Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti⁃IL⁃17A biologic for the treatment of psoriasis［J］. Ther Adv Chronic Dis, 2018,9（1）:5⁃21. doi: 10.1177/2040622317738910.
［8］	Maione F. Commentary: IL⁃17 in chronic inflammation: from discovery to targeting［J］. Front Pharmacol, 2016,7:250. doi: 10. 3389/fphar.2016.00250.
［9］	Isailovic N, Daigo K, Mantovani A, et al. Interleukin⁃17 and innate immunity in infections and chronic inflammation［J］. J Autoimmun, 2015,60:1⁃11. doi: 10.1016/j.jaut.2015.04.006.
［10］	Teunissen M, Yeremenko NG, Baeten D, et al. The IL⁃17A⁃producing CD8+ T⁃cell population in psoriatic lesional skin comprises mucosa⁃associated invariant T cells and conventional T cells［J］. J Invest Dermatol, 2014,134（12）:2898⁃2907. doi: 10.1038/jid.2014.261.
［11］	张洋洋, 李冰, 王刚. 银屑病皮损CD8αα+ T细胞表型鉴定［J］. 中华皮肤科杂志, 2018,51（10）:729⁃732. doi: 10.3760/cma.j.issn.0412⁃4030.2018.10.005.
［12］	Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL⁃17 through extracellular trap formation in psoriasis［J］. J Immunol, 2011,187（1）:490⁃500. doi: 10.4049/jimmunol. 1100123.
［13］	Kuwabara T, Ishikawa F, Kondo M, et al. The Role of IL⁃17 and related cytokines in inflammatory autoimmune diseases［J］. Mediators Inflamm, 2017,2017:3908061. doi: 10.1155/2017/390 8061.
［14］	Moos S, Mohebiany AN, Waisman A, et al. Imiquimod⁃induced psoriasis in mice depends on the IL⁃17 signaling of keratinocytes［J］. J Invest Dermatol, 2019,139（5）:1110⁃1117. doi: 10.1016/j.jid.2019.01.006.
［15］	Wu L, Chen X, Zhao J, et al. A novel IL⁃17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4⁃ERK5 axis［J］. J Exp Med, 2015,212（10）:1571⁃1587. doi: 10.1084/jem.20150204.
［16］	Gutowska⁃Owsiak D, Schaupp AL, Salimi M, et al. IL⁃17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion［J］. Exp Dermatol, 2012,21（2）:104⁃110. doi: 10.1111/j.1600⁃0625.2011.01412.x.
［17］	Nograles KE, Zaba LC, Guttman⁃Yassky E, et al. Th17 cytokines interleukin （IL）⁃17 and IL⁃22 modulate distinct inflammatory and keratinocyte⁃response pathways［J］. Br J Dermatol, 2008,159（5）:1092⁃1102. doi: 10.1111/j.1365⁃2133.2008.08769.x.
［18］	Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis［J］. J Invest Dermatol, 2009,129（9）:2175⁃2183. doi: 10.1038/jid.2009.65.
［19］	Schön MP, Erpenbeck L. The Interleukin⁃23/interleukin⁃17 axis links adaptive and innate immunity in psoriasis［J］. Front Immunol, 2018,9:1323. doi: 10.3389/fimmu.2018.01323.
［20］	Croxford AL, Karbach S, Kurschus FC, et al. IL⁃6 regulates neutrophil microabscess formation in IL⁃17A⁃driven psoriasiform lesions［J］. J Invest Dermatol, 2014,134（3）:728⁃735. doi: 10. 1038/jid.2013.404.
［21］	Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL⁃23/IL⁃17 signaling pathway and the treatment of psoriasis［J］. J Immunol, 2018,201（6）:1605⁃1613. doi: 10.4049/jimmunol.180 0013.
［22］	Sawyer L, Fotheringham I, Wright E, et al. The comparative efficacy of brodalumab in patients with moderate⁃to⁃severe psoriasis: a systematic literature review and network meta⁃analysis［J］. J Dermatolog Treat, 2018,29（6）:557⁃568. doi: 10.1080/09546634.2018.1427205.
［23］	Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up⁃to⁃date［J］. Expert Opin Biol Ther, 2019,19（4）:287⁃292. doi: 10.1080/14712598.2019.1579794.
［24］	Krueger JG, Wharton KA Jr, Schlitt T, et al. IL⁃17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis［J］. J Allergy Clin Immunol, 2019,144（3）:750⁃763. doi: 10.1016/j.jaci.2019.04.029.
［25］	McInnes IB, Nash P, Ritchlin C, et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta⁃analysis［J］. J Comp Eff Res, 2018,7（11）:1107⁃1123. doi: 10.2217/cer⁃2018⁃0075.
［26］	McInnes IB, Mease PJ, Schett G, et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study［J］. Arthritis Res Ther, 2018,20（1）:113. doi: 10.1186/s13075⁃018⁃1610⁃3.
［27］	Blauvelt A. Ixekizumab: a new anti⁃IL⁃17A monoclonal antibody therapy for moderate⁃to severe plaque psoriasis［J］. Expert Opin Biol Ther, 2016,16（2）:255⁃263. doi: 10.1517/14712598.2016. 1132695.
［28］	Ramaekers B, Wolff RF, Pouwels X, et al. Ixekizumab for treating moderate⁃to⁃severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal［J］. Pharmacoeconomics, 2018,36（8）:917⁃927. doi: 10.1007/s40273⁃018⁃0629⁃2.
［29］	Kemény L, Berggren L, Dossenbach M, et al. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER⁃2 and UNCOVER⁃3［J］. J Dermatolog Treat, 2019,30（1）:19⁃26. doi: 10.1080/09546634.2018.1473551.
［30］	Loos AM, Liu S, Segel C, et al. Comparative effectiveness of targeted immunomodulators for the treatment of moderate⁃to⁃severe plaque psoriasis: a systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2018,79（1）:135⁃144.e7. doi: 10.1016/j.jaad.2018.02.027.
［31］	van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52⁃week results from a phase III study （SPIRIT⁃P1）［J］. J Rheumatol, 2018, 45（3）: 367⁃377. doi: 10.3899/jrheum.170429
［32］	Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies［J］. J Allergy Clin Immunol, 2017,140（3）:645⁃653. doi: 10.1016/j.jaci.2017.07.004.
［33］	Mullard A. New plaque psoriasis approval carries suicide warning［J］. Nat Rev Drug Discov, 2017,16（3）:155. doi: 10.1038/nrd. 2017.44.
［34］	Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials［J］. J Am Acad Dermatol, 2018,78（1）:81⁃89.e5. doi: 10.1016/j.jaad.2017.08.024.
［35］	Lebwohl M. Reply to: "Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials"［J］. J Am Acad Dermatol, 2018,78（3）:e75. doi: 10.1016/j.jaad. 2017.11.028.
［36］	Rieder EA. In response to Lebwohl et al, "Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials"［J］. J Am Acad Dermatol, 2018,78（3）:e73. doi: 10.1016/j.jaad.2017.10.052.

白细胞介素17A在银屑病发病及治疗中的研究进展

Role of interleukin-17A in the occurrence and treatment of psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 0

Metrics

本文评价

推荐阅读 10